Prostate cancer trials in Brazil

In Brazil 26 Also abroad 1480

26 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Where
Porto Alegre, Rio de Janeiro, Santo André, São José do Rio Preto, São Paulo
Age
18 years and over
People
100 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07287150 · EU 2025-521327-67-00
Phase 3Taking people
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Where
Belo Horizonte, Bragança Paulista, Curitiba, Itajaí, Salvador, São Paulo, Vitória
Age
18 years and over
People
1,310 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00
Phase 3Taking people
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Where
Florianópolis, Joinville, Natal, Porto Alegre, São Paulo
Age
18 years and over
People
1,203 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07164443 · EU 2025-520927-26-00
Phase 3Taking people
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Where
Bauru, Natal, Santa Cruz do Sul, Santo André, São Paulo
Age
18 years and over
People
800 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07225946 · EU 2025-522713-29-00
Phase 3Taking people
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Where
Barretos, Brasília, Fortaleza, Natal, Porto Alegre, Salvador, Santo André, São José do Rio Preto, São Paulo
Age
18 years and over
People
900 worldwide
Run by
Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00
Phase 3Taking people
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Where
Belo Horizonte, Curitiba, Porto Alegre, São José do Rio Preto, São Paulo
Age
18 years and over
People
1,440 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00
Phase 1/2Taking people
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Where
Barretos, Porto Alegre, São Paulo
Age
18 years to 130 years
People
283 worldwide
Run by
AstraZeneca
See details and how to joinNCT07181161 · EU 2024-520026-11-00
Phase 3Taking people
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Where
São Paulo
Age
18 years to 100 years
People
450 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00
Phase 3Taking people
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Where
Belo Horizonte, Bragança Paulista, Curitiba, Fortaleza, Itajaí, Porto Alegre, Salvador, São José do Rio Preto, São Luís, São Paulo, Taubaté, Uberaba, Vitória
Age
18 years and over
People
1,314 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00
Phase 3Taking people
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Where
São Paulo
Age
18 years and over
People
670 worldwide
Run by
AstraZeneca
See details and how to joinNCT07611110
Phase 3Taking people
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Where
São Paulo
Age
18 years to 100 years
People
940 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06855277
Phase 3Taking people
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Where
Barretos, Brasília, Natal, Porto Alegre, São Caetano do Sul, São Paulo
Age
18 years and over
People
1,330 worldwide
Run by
AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00
Phase 3Taking people
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Where
Barretos, Cachoeiro de Itapemirim, Curitiba, Jaú, Londrina, Pelotas, Porto Alegre, Recife, Rio de Janeiro, Salvador, São Paulo
Age
18 years and over
People
700 worldwide
Run by
AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00
Phase 3Taking people
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Where
Curitiba, Fortaleza, Ijuí, Porto Alegre, Santo André, São José do Rio Preto, São Paulo, Sorocaba
Age
18 years and over
People
1,000 worldwide
Run by
Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00
Phase 1/2Taking people
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Where
Bragança Paulista, Natal, Porto Alegre, Ribeirão Preto, São José do Rio Preto, São Paulo
Age
18 years and over
People
360 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00
Phase 1/2Taking people
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Where
Porto Alegre
Age
18 years and over
People
181 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07190300 · EU 2025-521873-15-00
Phase 2/3Taking people
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Where
São Paulo
Age
18 years to 100 years
People
443 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06780670 · EU 2024-512342-42-00
Phase 1Taking people
Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma
Where
São Paulo
Age
18 years and over
People
18
Run by
Instituto do Cancer do Estado de São Paulo
See details and how to joinNCT07316686
No phaseTaking people
Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy
Where
São Paulo
Age
40 years and over
People
34
Run by
University of Sao Paulo
See details and how to joinNCT07463092
No phaseTaking people
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Where
Bela Vista, Bento Gonçalves, Curitiba, Porto Alegre, São Paulo
Age
21 years and over
People
5,000 worldwide
Run by
Prostate Cancer Clinical Trials Consortium
See details and how to joinNCT03151629
No phaseNot yet taking people in Brazil
PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort
Where
São Paulo
Age
18 years to 99 years
People
100
Run by
AstraZeneca
See details and how to joinNCT07560215
No phaseTaking people
Detecting Clinically Significant Prostate Cancer With Advanced MRI Protocols and Extensive Histopathology
Where
São Paulo
Age
18 years and over
People
300
Run by
Virdx, Inc.
See details and how to joinNCT07432360
Phase 2Taking people
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Where
Porto Alegre
Age
18 years and over
People
47 worldwide
Run by
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
See details and how to joinNCT04704505
Phase 4Taking people
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Where
Florianópolis, Natal, Passo Fundo, Porto Alegre, São Bernardo do Campo, São José do Rio Preto, São Paulo, Taguatinga
Age
18 years to 64 years
People
2,076 worldwide
Run by
Guerbet
See details and how to joinNCT04373564
No phaseNot yet taking people in Brazil
Proteomic Analysis of Patients Undergoing Bariatric Surgery
Where
Recife
Age
18 years and over
People
103
Run by
Universidade Federal de Pernambuco
See details and how to joinNCT06787807